## Juergen Prattes

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/359804/publications.pdf

Version: 2024-02-01

69 papers 2,381 citations

236833 25 h-index 233338 45 g-index

71 all docs

71 docs citations

71 times ranked

2101 citing authors

#	Article	IF	CITATIONS
1	COVID-19 in adult acute myeloid leukemia patients: a long-term follow-up study from the European Hematology Association survey (EPICOVIDEHA). Haematologica, 2023, 108, 22-33.	1.7	15
2	Risk factors and outcome of pulmonary aspergillosis in critically ill coronavirus disease 2019 patientsâ€"a multinational observational study by the European Confederation of Medical Mycology. Clinical Microbiology and Infection, 2022, 28, 580-587.	2.8	133
3	Aspergillus Lateral Flow Assay with Digital Reader for the Diagnosis of COVID-19-Associated Pulmonary Aspergillosis (CAPA): a Multicenter Study. Journal of Clinical Microbiology, 2022, 60, JCM0168921.	1.8	23
4	Prognostic Impact of Bronchoalveolar Lavage Fluid Galactomannan and Aspergillus Culture Results on Survival in COVID-19 Intensive Care Unit Patients: a <i>Post Hoc</i> Analysis from the European Confederation of Medical Mycology (ECMM) COVID-19-Associated Pulmonary Aspergillosis Study. Journal of Clinical Microbiology, 2022, 60, e0229821.	1.8	17
5	Utility of Serum 1,3- $\hat{l}^2$ - <scp>d</scp> -Glucan Testing for Diagnosis and Prognostication in COVID-19-Associated Pulmonary Aspergillosis. Microbiology Spectrum, 2022, 10, .	1.2	6
6	Invasive candidiasis: investigational drugs in the clinical development pipeline and mechanisms of action. Expert Opinion on Investigational Drugs, 2022, 31, 795-812.	1.9	23
7	Isavuconazole plasma concentrations in critically ill patients during extracorporeal membrane oxygenation. Journal of Antimicrobial Chemotherapy, 2022, 77, 2500-2505.	1.3	17
8	Performance of the Bronchoalveolar Lavage Fluid (i) Aspergillus (i) Galactomannan Lateral Flow Assay With Cube Reader for Diagnosis of Invasive Pulmonary Aspergillosis: A Multicenter Cohort Study. Clinical Infectious Diseases, 2021, 73, e1737-e1744.	2.9	48
9	Invasive pulmonary aspergillosis complicating COVID-19 in the ICU - A case report. Medical Mycology Case Reports, 2021, 31, 2-5.	0.7	83
10	Future challenges and chances in the diagnosis and management of invasive mould infections in cancer patients. Medical Mycology, 2021, 59, 93-101.	0.3	4
11	Implementation of rapid antimicrobial susceptibility testing combined with routine infectious disease bedside consultation in clinical practice (RAST-ID): a prospective single-centre study. Journal of Antimicrobial Chemotherapy, 2021, 76, 233-238.	1.3	12
12	Autopsy Proven Pulmonary Mucormycosis Due to Rhizopus microsporus in a Critically Ill COVID-19 Patient with Underlying Hematological Malignancy. Journal of Fungi (Basel, Switzerland), 2021, 7, 88.	1.5	79
13	Longitudinal Evaluation of Plasma Cytokine Levels in Patients with Invasive Candidiasis. Journal of Fungi (Basel, Switzerland), 2021, 7, 101.	1.5	3
14	Admission levels of Soluble Urokinase Plasminogen Activator Receptor (suPAR) are Associated with the Development of Severe Complications in Hospitalised COVID-19 Patients: A Prospective Cohort Study. International Journal of Infectious Diseases, 2021, 107, 188-194.	1.5	19
15	Diagnosis and treatment of COVID-19 associated pulmonary apergillosis in critically ill patients: results from a European confederation of medical mycology registry. Intensive Care Medicine, 2021, 47, 1158-1160.	3.9	43
16	Serum Lateral Flow assay with digital reader for the diagnosis of invasive pulmonary aspergillosis: A twoâ€eentre mixed cohort study. Mycoses, 2021, 64, 1197-1202.	1.8	14
17	Global guideline for the diagnosis and management of rare mould infections: an initiative of the European Confederation of Medical Mycology in cooperation with the International Society for Human and Animal Mycology and the American Society for Microbiology. Lancet Infectious Diseases, The. 2021. 21. e246-e257.	4.6	167
18	Antifungal prophylaxis for prevention of COVID-19-associated pulmonary aspergillosis in critically ill patients: an observational study. Critical Care, 2021, 25, 335.	2.5	61

#	Article	IF	CITATIONS
19	Soluble urokinase plasminogen activator receptor (suPAR) predicts critical illness and kidney failure in patients admitted to the intensive care unit. Scientific Reports, 2021, 11, 17476.	1.6	8
20	COVID-19 associated pulmonary aspergillosis: regional variation in incidence and diagnostic challenges. Intensive Care Medicine, 2021, 47, 1339-1340.	3.9	27
21	MixInYeast: A Multicenter Study on Mixed Yeast Infections. Journal of Fungi (Basel, Switzerland), 2021, 7, 13.	1.5	14
22	Aspergillus fumigatus and Its Allergenic Ribotoxin Asp f I: Old Enemies but New Opportunities for Urine-Based Detection of Invasive Pulmonary Aspergillosis Using Lateral-Flow Technology. Journal of Fungi (Basel, Switzerland), 2021, 7, 19.	1.5	4
23	The Antifungal Pipeline: Fosmanogepix, Ibrexafungerp, Olorofim, Opelconazole, and Rezafungin. Drugs, 2021, 81, 1703-1729.	4.9	168
24	COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA). Journal of Hematology and Oncology, 2021, 14, 168.	6.9	189
25	T2Candida magnetic resonance in patients with invasive candidiasis: Strengths and limitations. Medical Mycology, 2020, 58, 632-638.	0.3	15
26	SuPAR levels in BAL fluid from patients with acute respiratory distress syndromeâ€"a pilot study. Critical Care, 2020, 24, 576.	2.5	2
27	Variable Correlation between Bronchoalveolar Lavage Fluid Fungal Load and Serum-(1,3)-β-d-Glucan in Patients with Pneumocystosis—A Multicenter ECMM Excellence Center Study. Journal of Fungi (Basel,) Tj ETQq1	<b>1.6</b> .7843	1 <b>4</b> 2rgBT /0
28	The Aspergillus Lateral Flow Assay for the Diagnosis of Invasive Aspergillosis: an Update. Current Fungal Infection Reports, 2020, 14, 378-383.	0.9	14
29	Reply to Mikulska et al. Clinical Infectious Diseases, 2020, 73, e1784-e1785.	2.9	1
30	Acute respiratory distress syndrome during a pandemicâ€"an obvious diagnosis?. Lancet Infectious Diseases, The, 2020, 20, 873.	4.6	1
31	European confederation of medical mycology expert consultâ€"An ECMM excellence center initiative. Mycoses, 2020, 63, 566-572.	1.8	8
32	Baseline Chest Computed Tomography as Standard of Care in High-Risk Hematology Patients. Journal of Fungi (Basel, Switzerland), 2020, 6, 36.	1.5	15
33	Isavuconazole Treatment in a Mixed Patient Cohort with Invasive Fungal Infections: Outcome, Tolerability and Clinical Implications of Isavuconazole Plasma Concentrations. Journal of Fungi (Basel, Switzerland), 2020, 6, 90.	1.5	38
34	Blood Aspergillus PCR: The Good, the Bad, and the Ugly. Journal of Fungi (Basel, Switzerland), 2020, 6, 18.	1.5	26
35	Impact of ITS-Based Sequencing on Antifungal Treatment of Patients with Suspected Invasive Fungal Infections. Journal of Fungi (Basel, Switzerland), 2020, 6, 43.	1.5	5
36	Using Interleukin 6 and 8 in Blood and Bronchoalveolar Lavage Fluid to Predict Survival in Hematological Malignancy Patients With Suspected Pulmonary Mold Infection. Frontiers in Immunology, 2019, 10, 1798.	2.2	19

#	Article	IF	CITATIONS
37	Editorial: Diagnostic Approaches for Aspergillus Infections. Frontiers in Microbiology, 2019, 10, 446.	1.5	4
38	Immune Parameters for Diagnosis and Treatment Monitoring in Invasive Mold Infection. Journal of Fungi (Basel, Switzerland), 2019, 5, 116.	1.5	12
39	Triacetylfusarinine C: A urine biomarker for diagnosis of invasive aspergillosis. Journal of Infection, 2019, 78, 150-157.	1.7	38
40	Evaluation of the new <i>Asp</i> <scp>ID</scp> polymerase chain reaction assay for detection of <i>Aspergillus</i> species: A pilot study. Mycoses, 2018, 61, 355-359.	1.8	12
41	Clinical evaluation of the newly formatted lateralâ€flow device for invasive pulmonary aspergillosis. Mycoses, 2018, 61, 40-43.	1.8	55
42	Realâ€world challenges and unmet needs in the diagnosis and treatment of suspected invasive pulmonary aspergillosis in patients with haematological diseases: An illustrative case study. Mycoses, 2018, 61, 201-205.	1.8	27
43	2567. Diagnosis of Invasive Aspergillosis in Hematological Malignancy Patients Receiving Mold-Active Antifungals: Performance of Interleukin-6 and -8, Asp LFD, and Aspergillus PCR in Same-day Blood and Bronchoalveolar Lavage Fluid Samples. Open Forum Infectious Diseases, 2018, 5, S73-S73.	0.4	2
44	Serum 1,3-Beta-D-Glucan Values During and After Laparoscopic and Open Intestinal Surgery. Open Forum Infectious Diseases, 2018, 5, ofy296.	0.4	16
45	Evaluation of Galactomannan Testing, the Aspergillus-Specific Lateral-Flow Device Test and Levels of Cytokines in Bronchoalveolar Lavage Fluid for Diagnosis of Chronic Pulmonary Aspergillosis. Frontiers in Microbiology, 2018, 9, 2223.	1.5	23
46	Diagnosis of invasive aspergillosis in hematological malignancy patients: Performance of cytokines, Asp LFD, and Aspergillus PCR in same day blood and bronchoalveolar lavage samples. Journal of Infection, 2018, 77, 235-241.	1.7	78
47	Spotlight on isavuconazole in the treatment of invasive aspergillosis and mucormycosis: design, development, and place in therapy. Drug Design, Development and Therapy, 2018, Volume 12, 1033-1044.	2.0	75
48	Galactomannan testing and <i>Aspergillus </i> PCR in same-day bronchoalveolar lavage and blood samples for diagnosis of invasive aspergillosis. Medical Mycology, 2017, 55, myw102.	0.3	65
49	Invasive aspergillosis in patients with underlying liver cirrhosis: a prospective cohort study. Medical Mycology, 2017, 55, 803-812.	0.3	22
50	Levels of interleukin ( <scp>IL</scp> )â€6 and <scp>IL</scp> â€8 are elevated in serum and bronchoalveolar lavage fluid of haematological patients with invasive pulmonary aspergillosis. Mycoses, 2017, 60, 818-825.	1.8	39
51	Prognostic and diagnostic potential of suPAR levels in pleural effusion. Journal of Infection, 2017, 75, 465-467.	1.7	6
52	1,3-ß-d-Glucan testing is highly specific in patients undergoing dialysis treatment. Journal of Infection, 2017, 74, 72-80.	1.7	16
53	Bronchoalveolar lavage triacetylfusarinine C (TAFC) determination for diagnosis of invasive pulmonary aspergillosis in patients with hematological malignancies. Journal of Infection, 2017, 75, 370-373.	1.7	34
54	Diagnostic Performance Of Bronchoalveolar Lavage Triacetylfusarinine C (TAFC) Determination for Invasive Pulmonary Aspergillosis In Patients With Hematological Malignancies. Open Forum Infectious Diseases, 2016, 3, .	0.4	2

#	Article	IF	CITATIONS
55	Posaconazole plasma exposure correlated to intestinal mucositis in allogeneic stem cell transplant patients. European Journal of Clinical Pharmacology, 2016, 72, 953-963.	0.8	21
56	Point of Care Testing for the Diagnosis of Fungal Infections: Are We There Yet?. Current Fungal Infection Reports, 2016, 10, 43-50.	0.9	37
57	Chemotherapy-Induced Intestinal Mucosal Barrier Damage: a Cause of Falsely Elevated Serum 1,3-Beta- <scp>d</scp> -Glucan Levels?. Journal of Clinical Microbiology, 2016, 54, 798-801.	1.8	17
58	Urine Galactomannan-to-Creatinine Ratio for Detection of Invasive Aspergillosis in Patients with Hematological Malignancies. Journal of Clinical Microbiology, 2016, 54, 771-774.	1.8	20
59	Prognostic potential of 1,3-beta-d-glucan levels in bronchoalveolar lavage fluid samples. Journal of Infection, 2016, 72, 29-35.	1.7	16
60	Diagnostic accuracy of the <i>Aspergillus</i> ≥â€specific bronchoalveolar lavage lateralâ€flow assay in haematological malignancy patients. Mycoses, 2015, 58, 461-469.	1.8	51
61	Reliability of serum 1,3â€betaâ€ <scp>d</scp> â€glucan assay in patients undergoing renal replacement therapy: a review of the literature. Mycoses, 2015, 58, 4-9.	1.8	29
62	Influence of mould-active antifungal treatment on the performance of the Aspergillus-specific bronchoalveolar lavage fluid lateral-flow device test. International Journal of Antimicrobial Agents, 2015, 46, 401-405.	1.1	73
63	Bronchoalveolar lavage fluid sample pretreatment with Sputasol® significantly reduces galactomannan levels. Journal of Infection, 2015, 70, 541-543.	1.7	17
64	Multicenter evaluation of a lateral-flow device test for diagnosing invasive pulmonary aspergillosis in ICU patients. Critical Care, 2015, 19, 178.	2.5	65
65	Detection of (1→3)â€Î²â€ <scp>D</scp> â€glucan in sameâ€day urine and serum samples obtained from patients haematological malignancies. Mycoses, 2015, 58, 394-398.	with 1.8	13
66	Characteristics of Hospital-Acquired and Community-Onset Blood Stream Infections, South-East Austria. PLoS ONE, 2014, 9, e104702.	1.1	31
67	Predictors of H1N1 influenza in the emergency department: proposition for a modified H1N1 case definition. Clinical Microbiology and Infection, 2014, 20, O105-O108.	2.8	9
68	Comparison of clinical presentation and laboratory values at admission between PCR-confirmed influenza A H1N1 infection and influenza-like disease, South-East Austria. Infection, 2014, 42, 317-324.	2.3	1
69	Novel Tests for Diagnosis of Invasive Aspergillosis in Patients with Underlying Respiratory Diseases. American Journal of Respiratory and Critical Care Medicine, 2014, 190, 922-929.	2.5	113